Journal
VACCINES
Volume 9, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/vaccines9121392
Keywords
immunotherapy; T-cell; vaccine; cancer; checkpoint inhibition; microbiome; metabolism
Categories
Ask authors/readers for more resources
Cancer vaccination and immunotherapy have revolutionized cancer treatment, but only a minority of patients respond to this treatment and some cancers are resistant to it. CD4(+) and CD8(+) alpha beta T-cells play a crucial role in the anti-tumor immune response, but their function is often compromised in cancer patients.
Cancer vaccination and immunotherapy revolutionised the treatment of cancer, a result of decades of research into the immune system in health and disease. However, despite recent breakthroughs in treating otherwise terminal cancer, only a minority of patients respond to cancer immunotherapy and some cancers are largely refractive to immunotherapy treatment. This is due to numerous issues intrinsic to the tumour, its microenvironment, or the immune system. CD4(+) and CD8(+) alpha beta T-cells emerged as the primary effector cells of the anti-tumour immune response but their function in cancer patients is often compromised. This review details the mechanisms by which T-cell responses are hindered in the setting of cancer and refractive to immunotherapy, and details many of the approaches under investigation to direct T-cell function and improve the efficacy of cancer vaccination and immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available